AdvisorShares迷幻药主动型ETF PSIL 深 沪
已收盘 05-22 16:00:00 美东时间
21.13
+0.679
+3.32%
华盛通- 最 高21.1599
- 今 开20.75
- 成交量 3.86万股
- 最 低 20.55
- 昨 收 20.4508
- 总市值 3592.05万
- 52周最高 22.49
- 市盈率 静 --
- 换手率 2.27%
- 52周最低 11.3442
- 委 比 0.00%
- 总股本 170.00万
- 历史最高 104.3816
- 量 比 1.54
- 振 幅 2.98%
- 历史最低 5.9573
- 每 手 1
- 风险率 2.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NRx Pharma Stock Jumps After FDA Signals Path To NDA For Ketamine Depression Drug
The FDA signals its willingness to review NRx Pharmaceuticals' NRX-100 NDA, boosting optimism around its depression treatment.
03-17 01:35
Pacifica Silver Expands Claudia Drilling and Bolsters Exploration Team
Pacifica Silver ( ($TSE:PSIL) ) has provided an update. Pacifica Silver has exp...
03-16 21:44
COMPASS Pathways Triumph In Hard To Treat Depression Ignites Investor Frenzy
Compass Pathways' stock surges after late-stage depression trial success.
02-17 22:12
BRIEF-Psyence BioMed Announces Approval For Use Of Psylabs’ Psilocybin Product In Phase IIb Clinical Trial
Dec 19 (Reuters) - Psyence Biomedical Ltd PBM.O: PSYENCE BIOMED ANNOUNCES APPROVAL FOR USE OF PSYLABS’ PSILOCYBIN PRODUCT IN PHASE IIB CLINICAL TRIAL PSYENCE BIOMEDICAL LTD: STUDY REMAINS ON TRACK TO ...
2025-12-19 20:06
Quantum Biopharma Reports Positive Phase 1 Safety For Multiple Sclerosis Drug
Quantum Biopharma's subsidiary, Huge Biopharma Australia, has cleared a regulatory milestone for its neuroprotective compound, Lucid-MS, in a Phase 1 trial.
2025-08-06 02:25
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors
Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more.
2025-05-25 04:11
BRIEF-Mercedes-Benz Announces Adam Chamberlain To Succeed Dimitris Psillakis As CEO Of Mercedes-Benz USA
April 15 (Reuters) - Mercedes-Benz Group AG MBGn.DE: MERCEDES-BENZ ANNOUNCES LEADERSHIP TRANSITION: ADAM CHAMBERLAIN TO SUCCEED DIMITRIS PSILLAKIS AS CEO OF MERCEDES-BENZ USA MERCEDES-BENZ USA: DIMITR...
2025-04-16 06:01
BRIEF-Benuvia Operations Awarded NIH Contract For GMP Synthesis Of Psilocybin And Other Bulk Drug Substances
March 25 (Reuters) - BENUVIA OPERATIONS- AWARDED NIH CONTRACT FOR GMP SYNTHESIS OF PSILOCYBIN AND OTHER BULK DRUG SUBSTANCES Source text: ID:nPn78PbBha ((Reuters.Briefs@thomsonreuters.com;))
2025-03-25 21:14
